Enalapril

DRUG INFORMATION

  ADULT
    - Hypertension • Adult: recommended initial dose is 5 mg once daily.
      Source: US FDA label for enalapril (Enalapril maleate oral solution), section
      'dosage and administration', retrieved 2026-08-29
    - ( 2.1 ) Heart Failure: Initiate at 2.5 mg twice daily.
      Source: US FDA label for enalapril (Enalapril maleate oral solution), section
      'dosage and administration', retrieved 2026-08-29
    - Titrate up to 20 mg twice daily as tolerated.
      Source: US FDA label for enalapril (Enalapril maleate oral solution), section
      'dosage and administration', retrieved 2026-08-29

  CHILD
    - Neonates with a history of in utero exposure to enalapril maleate If oliguria or
      hypotension occurs, direct attention toward support of blood pressure and renal
      perfusion. Exchange transfusions or dialysis may be required as a means of
      reversing hypotension and/or substituting for disordered renal function.
      Source: US FDA label for enalapril (Enalapril maleate oral solution), section
      'pediatric use', retrieved 2026-08-29
    - Hypertension • Adult: recommended initial dose is 5 mg once daily. Maximum dose is
      40 mg daily. ( 2.1 ) • Pediatrics: recommended starting dose is 0.08 mg/kg (up to
      5 mg) once daily. ( 2.1 ) Heart Failure: Initiate at 2.5 mg twice daily. Titrate
      up to 20 mg twice daily as tolerated. ( 2.2 ) Asymptomatic Left Ventricular
      Dysfunction: Initiate at 2.5 mg twice daily. Titrate up to 10 mg twice daily.
      Source: US FDA label for enalapril (Enalapril maleate oral solution), section
      'dosage and administration', retrieved 2026-08-29
    - ( 2.1 ) • Pediatrics: recommended starting dose is 0.08 mg/kg (up to 5 mg) once
      daily.
      Source: US FDA label for enalapril (Enalapril maleate oral solution), section
      'dosage and administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - Dosage Adjustment for Renal Impairment: See table below.
      Source: US FDA label for enalapril (Enalapril maleate oral solution), section
      'dosage and administration', retrieved 2026-08-29
    - Renal Status Creatinine-Clearance mL/min Initial Dose mg/day Normal or Mild
      Impairment of Renal Function >30 mL/min 5 mg Moderate to Severe Impairment ≤30
      mL/min 2.5 mg Dialysis Patients*† – 2.5 mg * = [See Warnings and Precautions ( 5.2
      )]. † = Should be taken after hemodialysis on dialysis days [see Clinical
      Pharmacology 12.3 )] .
      Source: US FDA label for enalapril (Enalapril maleate oral solution), section
      'dosage and administration', retrieved 2026-08-29
    - Exchange transfusions or dialysis may be required as a means of reversing
      hypotension and substituting for disordered renal function. 8.2 Lactation Risk
      Summary Enalapril and enalaprilat have been detected in human breast milk.
      Source: US FDA label for enalapril (Enalapril maleate oral solution), section 'use
      in specific populations', retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for enalapril (Enalapril maleate
      oral solution), retrieved 2026-08-29

  PREGNANCY
    - Risk Summary Enalapril maleate can cause fetal harm when administered to a
      pregnant woman.
      Source: US FDA label for enalapril (Enalapril maleate oral solution), section
      'pregnancy', retrieved 2026-08-29
    - Use of drugs that act on the renin-angiotensin system during the second and third
      trimesters of pregnancy reduces fetal renal function and increases fetal and
      neonatal morbidity and death.
      Source: US FDA label for enalapril (Enalapril maleate oral solution), section
      'pregnancy', retrieved 2026-08-29
    - Most epidemiologic studies examining fetal abnormalities after exposure to
      antihypertensive use in the first trimester have not distinguished drugs affecting
      the renin-angiotensin system from other antihypertensive agents.
      Source: US FDA label for enalapril (Enalapril maleate oral solution), section
      'pregnancy', retrieved 2026-08-29

  BREASTFEEDING
    - ( 8.4 ) • Lactation: Advise not to breastfeed.
      Source: US FDA label for enalapril (Enalapril maleate oral solution), section 'use
      in specific populations', retrieved 2026-08-29
    - Exchange transfusions or dialysis may be required as a means of reversing
      hypotension and substituting for disordered renal function. 8.2 Lactation Risk
      Summary Enalapril and enalaprilat have been detected in human breast milk.
      Source: US FDA label for enalapril (Enalapril maleate oral solution), section 'use
      in specific populations', retrieved 2026-08-29
    - Because of the potential for severe adverse reactions in the breastfed infant,
      including hypotension, hyperkalemia and renal impairment, advise women not to
      breastfeed during treatment with enalapril maleate. 8.4 Pediatric Use Neonates
      with a history of in utero exposure to enalapril maleate If oliguria or
      hypotension occurs, direct attention toward support of blood pressure and renal
      perfusion.
      Source: US FDA label for enalapril (Enalapril maleate oral solution), section 'use
      in specific populations', retrieved 2026-08-29